Mohamed Elghetany

Update Your Profile
Profile URL: www.utmb.edu/pathology/profiles/?user=melgheta
Mohamed Elghetany
Contact Information
Email:

Directory lookup

Academic Appointments
Appointment Organization
Professor Pathology
Director of Path Patient Services Pathology
Professional Education
Degree Institution Field of Study Graduation Year
Certificate of Business Administration University of Houston at Clear Lake 1999
Fellowship State University of New York-Health Science Center Hematopathology 1990
Residency Baylor College of Medicine Pathology (combined AP/CP), 1988
Chief Resident Ain Shams University Hospital Internal Medicine & Endocrinology 1983
Resident Ain Shams University Hospital Internal Medicine 1983
Masters degree in Internal Medicine (M.Sc.) Ain Shams University 1983
Rotating Intern Ain Shams University Hospital 1981
Diploma of Medicine and Surgery (M.B., B.Ch.) Ain Shams University School of Medicine 1979
Honors
Title Organization Year(s)
Course Commendation for Excellence in PBL Teaching, Pathobiology and Host Defenses Course, April 2001. 2001
Travel Award ($1000) for abstract presentation, the International Scientific Meeting on Shwachman-Diamond Syndrome, Verona, Italy, April 2001 2001
Best Clinical Pathology Faculty Award for active participation in resident teaching, Department of Pathology, UTMB, Galveston, TX. 2001
Best Clinical Pathology Faculty Award for active participation in resident teaching, Department of Pathology, UTMB, Galveston, TX. 1998
Best Clinical Pathology Faculty Award for active participation in resident teaching, Department of Pathology, UTMB, Galveston, TX. 1997
Best Clinical Pathology Faculty Award for active participation in resident teaching, Department of Pathology, UTMB, Galveston, TX. 1996
Best Clinical Pathology Faculty Award for active participation in resident teaching, Department of Pathology, UTMB, Galveston, TX. 1995
Cairo Medical Association's "Doctor of the Year" Award during residency. 1983
Graduation with highest honors in the top 2% of a class of 800 students, Ain Shams University School of Medicine, Cairo, Egypt. 1979
Professional Affiliations
Society Year(s)
Member, The American Society of Hematology -
Member, The International Society for Laboratory Hematology -
Member, The International Society on Thrombosis and Hemostasis -
Member, The United States and Canadian Academy of Pathology -
Member, The Myelodysplastic Syndrome Foundation -
Fellow, The American Society of Clinical Pathologists -
Member, Houston Society of Clinical Pathologists -
Member, Texas Society of Pathologists -
Fellow, The College of American Pathologists -
Research Interests

The Diagnosis of Blood Disorders

As a hematopathologist, I am involved in the diagnosis of blood diseases including leukemias, lymphomas and bleeding disorders.

In collaboration with the cancer and leukemia group B (CALGB), I have reviewed and verified the diagnosis of hundreds of cases with acute leukemia and myelodysplastic syndromes (MDS).

A major area of my interest is the MDS. This group of diseases is characterized by abnormal production and maturation of blood cells. MDS tend to have a characteristic morphology associated with abnormal function of individual cells. The myelodysplastic syndromes are associated with bone marrow failure in addition to increased risk for the development of acute leukemia. MDS in children are even more challenging. The French American British (FAB) and the World Health Organization (WHO) classifications of MDS do not apply very well to the pediatric group. Inherited bone marrow failure syndromes may evolve into MDS and this could pose a diagnostic problem.

In collaboration with the Shwachman Diamond Syndrome International Foundation and with the National Institute of Health, we are studying patients with this rare syndrome and other bone marrow failure syndromes to assess the use of various makers to predict and correlate with the development of MDS. The outcome of MDS development in these syndromes is not clear. We are applying morphologic, cytochemical, immunohistochemical and flow cytometric methodologies in this study. This study is being expanded to acquired cytopenias, including acquired aplastic anemia.

Selected Publications
  1. Elghetany MT, Ge Y, Patel J, Martinez J, Uhrova H. Flow cytometric study of neutrophilic granulopoiesis in normal bone marrows using an expanded panel of antibodies: correlation with morphologic assessment. J Clin Lab Anal 18:36-41, 2004
  2. Elghetany MT, Lacombe F. Physiologic variations in granulocytic surface antigen expression: impact of age, gender, pregnancy, race, and stress. J Leukoc Biol 75:157-62, 2004
  3. Ge Y, Elghetany MT. Urokinase plasminogen activator receptor (CD87): something old, something new. Lab Hematol 9:67-71, 2003
  4. Elghetany MT, Patel J, Martinez J, Schwab H. CD87 as a marker for terminal granulocytic maturation: assessment of its expression during granulopoiesis. Cytometry 51B:9-13, 2003
  5. Elghetany MT: Surface antigen changes during normal neutrophilic development: a critical review. Blood Cells Mol Dis 28:260-274, 2002
  6. Elghetany MT. Fine needle aspiration cytology of Castleman’s disease. ASCP Check Sample C-02-7 (C-337), 2002
  7. Elghetany MT, Molina CP, Patel J, Martinez J, Schwab H, Velagaleti GVN. Expression of CD4 on peripheral blood granulocytes: a novel finding in a case of myelodysplastic syndrome in association with translocation (5;12). Cancer Genet Cytogenet 136:38-42, 2002
  8. Elghetany MT, Alter BP. P53 protein overexpression in bone marrows of patients with Shwachman-Diamond syndrome has a prevalence similar to patients with refractory anemia. Arch Pathol Lab Med 126:452-455, 2002
  9. Elghetany MT, Patel J. Assessment of CD24 expression on bone marrow neutrophilic granulocytes: CD24 is a marker for the myelocytic stage of development. Am J Hematol 71:348-349, 2002
  10. Rothbaum R, Perrault Jean, Vlachos A, Cipolli M, Alter BP, Burroughs S, Durie P, Elghetany MT, Grand R, Hubbard V, Rommens J, Rossi T. Shwachman-Diamond syndrome – A conference report. J Pediatr 141:266-270, 2002
  11. Mathew P, Hudnall SD, Elghetany MT, Payne DA. T-gamma gene rearrangement and CMV mononucleosis. Am J Hematol 66:64-66, 2001
  12. Okorodudu AO, Yang H, Elghetany MT. Ionized magnesium in the homeostasis of cells: intracellular threshold for Mg++ in human platelets. Clinica Chimica Acta 303:147-154, 2001
  13. Kumar M, Sackey K, Schmalstieg F, Trizna Z, Elghetany MT, Alter BP. Griscilli Syndrome: rare neonatal syndrome with recurrent hemophagocytosis. Am J Pediatr Hematol Oncol 23:464-468, 2001.
  14. Youh C, Elghetany MT, Petersen JR, Mohammad A, Okorodudu AO. Accuracy and precision of point-of-care testing for glucose and prothrombin time at the critical care units. Clinica Chimica Acta 307:119-123, 2001
  15. Schmaier AH, Srikanth S, Elghetany MT, Normolle D, Gokhale S, Feng H-M, Walker DH. Hemostatic/fibrinolytic protein changes in C3H/HeN mice infected with Rickettsia conorii. A model Rocky Mountain spotted fever. Thromb Haemost 86:871-879, 2001
  16. Elghetany MT. p53 overexpression in bone marrow biopsies in refractory anemia and aplastic anemia: impact of antibody selection. Leukemia Res 24:975-977, 2000
  17. Gopal S, Awasthi S, Elghetany MT. Bilateral breast MALT lymphoma: A case report and review of the literature. Ann Hematol 79:86-89, 2000
  18. Popnikolov NK, Payne DA, Hudnall SD, Hawkins HK, Kumar M, Norris BA, Elghetany MT. CD13-positive anaplastic large cell lymphoma of T-cell origin-a diagnostic and histogenetic problem. Arch Pathol Lab Med 124:1804-1808, 2000
  19. Elghetany MT. Significance of p21waf-1 protein immunohistochemical staining in aplastic anemia and refractory anemia: correlation with p53 protein overexpression. Lab Hematol 6:133-136, 2000
  20. Alter BP, Caruso JP, Drachtman RA, Uchida T, Velagaleti GVN, Elghetany MT. Fanconi’s anemia: Myelodysplasia as a predictor of outcomes. Cancer Genet Cytogenet 117:125-131, 2000
  21. Rao LV, Okorodudu AO, Petersen JR, Elghetany MT. Stability of prothrombin time and activated partial thromboplastin time tests under different storage conditions. Clinica Chimica Acta 300:13-21, 2000
  22. Elghetany MT. Double esterase staining of the bone marrow contributes to lineage identification in a case of minimally-differentiated acute myeloid leukemia (AML-M0). Clin Lab Haematol 21:293-295, 1999
  23. Elghetany MT, Walker DH. Hemostatic changes in Rocky Mountain spotted fever and Mediterranean spotted fever: a review. Am J Clin Pathol 112:159-168, 1999
  24. Elghetany MT. Surface marker abnormalities in the myelodysplastic syndromes. Haematologica 83:1104-1115, 1998
  25. Elghetany MT, MacCallum J, Nelson DA, Varney JF, Sullivan AK, Silverman LR, Schiffer CA, Davey FR, Bloomfield CD. Double esterase staining and other neutrophilic granule abnormalities in 237 patients with the myelodysplastic syndromes studied by the Cancer and Leukemia Group B. Acta Haematol 100:13-16, 1998
  26. Elghetany MT, Vyas S, Youh G. Significance of p53 overexpression in bone marrow biopsies from patients with bone marrow failure: aplastic anemia, hypocellular refractory anemia, and hypercellular refractory anemia. Ann Hematol 77:261-264, 1998
  27. Elghetany MT, Hudnall SD, Gardner FH. Peripheral blood picture in primary hypocellular refractory anemia and idiopathic acquired aplastic anemia: an additional tool for differential diagnosis. Haematologica 82:21-24, 1997
  28. Elghetany MT. True histiocytic lymphoma: is it an entity? Leukemia 11:762-764, 1997
  29. Elghetany MT. Hodgkin’s disease coexisting with myelodysplastic syndrome prior to therapy: a case report and a review of the association of Hodgkin’s disease with stem cell disorders. Ann Hematol 75:231-234, 1997
  30. Elghetany MT, MacCallum J, Nelson DA, Varney JF, Sullivan AK, Silverman LR, Schiffer CA, Davey FR, Bloomfield CD. Deficiency of neutrophilic granule membrane glycoproteins in the myelodysplastic syndromes: a common deficiency in 216 patients studied by the Cancer and Leukemia Group B. Leukemia Res 21:801-806, 1997
  31. Elghetany MT, Sullivan AK, Kurec AS, MacCallum JM, Bloomfield CD, Sobel RE, Davey FR. The use of monoclonal antibodies against primary myeloid granules in normal and leukemia cells. Am J Clin Pathol 98: 430-436, 1992
  32. Elghetany MT, Kurec AS, Schuehler K, Forbes BA, Duggan D, Davey FR. Immunophenotyping of non-Hodgkins's lymphomas in paraffin-embedded tissue sections: A comparison with genotypic analysis. Am J Clin Pathol 95: 517-525, 1991
  33. Ball ED, Davis RB, Griffin JD, Mayor RJ, Davey FR, Arthur DC, Wursker-Hill D, Noll W, Elghetany MT, Allen SL, Rai K, Lee EJ, Schiffer CA, Bloomfield CD. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 77:2242 - 2250, 1991
  34. Davey FR, Elghetany MT, Kurec AS. Immunophenotyping of hematologic neoplasms in paraffin-embedded tissue sections. Am J Clin Pathol 93(suppl 1):17-26, 1990
  35. Elghetany MT, MacCallum J, Davey FR. The use of cytochemical procedures in the diagnosis and management of acute and chronic myeloid leukemia. Clin Lab Med 10:707-720, 1990
  36. Elghetany MT, Saleem A. The Congo red stain revisited. Ann Clin Lab Sci 19:190-195, 1989
  37. Elghetany MT, Banez EI. Granulocytic sarcoma manifested as ascites: report of a case. South Med J 82:1439-1440, 1989
  38. Elghetany MT, Saleem A. Methods for staining amyloid in tissue: A review. Stain Technol 63:201-212, 1988

Search PubMed database for Mohamed Elghetany